We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non-invasive Test for Gastroparesis Developed for Routine Diagnostic Use

By Biotechdaily staff writers
Posted on 06 Jun 2007
A non-invasive test for gastroparesis, a chronic stomach condition characterized by nausea, vomiting, and abdominal pain, is now available for routine clinical diagnostic use.

The University of Kansas Hospital (Kansas City, USA) is one of the first in the United States to offer the SmartPill pH.p Capsule as a standard clinical test. More...
SmartPill, manufactured by SmartPill Corp. (Buffalo, NY, USA) is an ingestible, wireless capsule that measures pressure, pH, and temperature as it transits the gastrointestinal (GI) tract. This information is used to provide gastric emptying time, combined small and large bowel transit time, total transit time, pressure contraction patterns from the antrum and duodenum, and motility indices.

The capsule, which is somewhat larger than a multi-vitamin (26 mm x 13 mm), is administered in a physician's office. Since the SmartPill test is ambulatory, the patient is free to continue with his normal routine during the course of the assay. As the capsule passes through the GI tract, it transmits data to a data receiver worn by the patient. Once the single-use capsule has passed from the body, the patient returns the data receiver to the physician, who then downloads the collected data to a personal computer. The physician then uses a dedicated software package to analyze and display the data. Test results in both graphic and report formats are available within a few minutes.

While SmartPill in its present form cannot replace procedures such as endoscopy and colonoscopy, it may be used instead of gastric-emptying scintigraphy, which exposes a patient to radiation, and manometry, which involves the use of pressure catheters, inserted through the mouth and/or rectum.

"Some gastroparesis patients cannot really leave their house because of their problems. Often, these patients are losing weight because of limited nutritional intake,” explained Dr. Richard McCallum, professor of gastroenterology at the University of Kansas Hospital. "This new technology will allow us to give these patients the treatment they need much sooner and with a non-invasive safe and well-tolerated test with standardized results for better patient outcomes.”


Related Links:
University of Kansas Hospital
SmartPill

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gas Analyzer
GE SAM
New
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.